Page 10 - Diffusion Pharmaceuticals News Today

Good morning, investor! It's time to get into the thick of it with a dive into the biggest pre-market stock movers for Tuesday!

The fears around the spread of the coronavirus have returned to haunt people around the world as governments scramble to contain Omicron, a new variant of COVID-19 that has been designated as “high ...

With a new year fast approaching, these biotech penny stocks may benefit from the shifting winds in the broader healthcare market.

Gainers

Gainers Enzo Biochem (NYSE:ENZ) stock increased by 8.49% to $3.45 during Wednesday’s after-market session. Today’s trading volume for this security ended up closing at 1.2 million shares, which is 104.38 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $166.3 million. The company’s, Q3 earnings came out today. Bellicum Pharmaceuticals (NASDAQ:BLCM) shares increased by 7.78% to $3.6. Bellicum Pharmaceuticals’s trading volume hit 4....

Gainers VistaGen Therapeutics (NASDAQ:VTGN) stock rose 22.6% to $2.82 during Wednesday’s after-market session. This security traded at a volume of 1.3 million shares come close, making up 46.76% of its average volume over the last 100 days. The company’s market cap stands at $536.3 million. PolarityTE (NASDAQ:PTE) stock rose 9.27% to $1.07. At the close, PolarityTE’s trading volume reached 478.5K shares. This is 9.86% of its average volume over the last 100 days. The market value of thei...

Tasadenoturev (DNX-2401) by VBI Vaccines, Aivita Biomedical, Immunomic Therapeutics, and DNAtrix, respectively. Discoveries of isocitrate dehydrogenase (IDH) mutation, co-deletion of the short arm of chromosome 1 and the long arm of chromosome 19 (1p19q), O6-methylguanine-DNA methyltransferase (MGMT) gene promoter methylation, and histone H3-K27M mutation have led to a better understanding of the molecular aberrations associated with Brain Tumors. Pondering over changing dynamics of the Brain ...

(1) LAS VEGAS, March 4, 2021 /PRNewswire/ -- Rare cancers account for approximately 22% of all the diagnosed cancer cases. The US National Cancer Institute defines rare cancers as those with an incidence of less than 15 cases per 100?000 per year. However, these cases are not confined to one or the other particular geography, but are disproportionately spread across the world. Many rare human cancers are not curable, and have limited number of treatment options. Rare cancers are more difficult ...

Gainers ClearPoint Neuro (NASDAQ:CLPT) stock rose 8.48% to $27.99 during Thursday's after-market session. This security traded at a volume of 10.5K ...

(1) BASEL (dpa-AFX) - Todays Daily Dose brings you news about temporary suspension of bluebird bios gene therapy trials in sickle cell disease, Sesen Bios regulatory catalyst for this year, partial hold on Cortexymes open-label extension phase of its ongoing phase II/III study of Atuzaginstat for Alzheimers disease, and expanded FDA approval of Novartis Entresto. Read on. 1. Sickle Cell Disease Trial Blues For bluebird bio Shares of bluebird bio Inc. (BLUE) slumped to a 5-year low on Tuesday as...